Main description:

With over 10 million new TB cases and 1.6 million deaths, TB is a global health priority. Multidrug-resistant TB is of particular concern to both clinicians and national TB programmes: in 2017, there were 558 000 new rifampicin-resistant cases and 460 000 confirmed multidrug-resistant TB cases. Despite extensive investigation over the years, there is still a great deal to learn about the prevention, diagnosis and treatment of TB. This Monograph brings together chapters from global TB experts and begins with a patients' perspective that sets the tone. The following chapters cover: the history of TB; epidemiology; strategies for control and elimination; clinical and laboratory diagnosis; imaging; treatment and drugs; TB in children and different patient populations; comorbidities; clinical cases; and much more.

Contents:

The patients' perspective; History of tuberculosis; Epidemiology and socioeconomic determinants; Evolution of the strategies for control and elimination; Aetiopathogenesis, immunology and microbiology; Clinical diagnosis; Laboratory diagnosis; Imaging for diagnosis and management; Bronchoscopy and other invasive procedures for diagnosis; Treatment of drug-susceptible and drug-resistant tuberculosis; New and repurposed drugs; Adverse anti-tuberculosis drug events and their management; Surgery as a treatment; Challenges in childhood tuberculosis; Pregnancy and the elderly; Comorbidities; Access and adherence to prevention and care for hard-to-reach groups; Monitoring during and after treatment; Sequelae assessment and rehabilitation; Towards a new vaccine; Transmission control: a refocused approach; Diagnosis and treatment of latent tuberculosis infection; Nontuberculous mycobacteria; What next? Basic research, new treatments and a patient-centred approach; Opportunities for training and learning; Clinical cases.